

ASX Announcement

8 May 2026

BOARD REORGANISATION

Genetic Signatures Limited (SX: GSS) (“GSS” or “the Company”), today announced the reorganisation of its Board as part of the Company’s continued drive towards efficiency, while sharpening its focus on strategic priorities and governance responsibilities.

Specifically, the Board has reviewed its size, composition and skills to ensure alignment with the Company’s position and its needs going forward. The Board notes the progress made by the Chief Executive Officer, Ms Maria Halasz, against the Company’s objectives through a material reduction of fixed costs and commencing the implementation of an outsourced business model, reflecting its focus on building a leaner and more scalable operational foundation. These considerations have resulted in the following changes which will take effect at close of business on 8 May 2026:

- Ms Anne Lockwood will conclude her role as Interim Managing Director and continue in her position as Non-Executive Director and Chair of the Audit Committee.
- Dr Neil Gunn will resign from his role as Non-Executive Director.
- The Company’s current Financial Controller Ms Angela Wang who has worked closely with Ms Lockwood and the CEO during the CEO transition will report to the CEO.

These changes also have the benefit of reducing the Company’s cost base without compromising the Board’s governance responsibilities.

All other directors, Ms Caroline Waldron, Mr Mike Aicher and Dr Jenny Harry, will continue their service on the Board and, together with Ms Lockwood, will be responsible for the continued oversight of both the CEO’s and the Company’s performance.

Genetic Signatures’ Chair, Ms Waldron said, “The Board thanks Dr Gunn and Ms Lockwood for their significant contributions to the Company, particularly for their willingness to step into management roles when needed during critical leadership transition periods. We wish Dr Gunn all the best in his future endeavours.”

The Company remains focused on assessing its commercial strategy and the most effective pathways to reset the US operations with the ongoing input from its highly experienced US based Non-Executive Director, Mr Mike Aicher.

With a skilled and committed Board and senior team, and a strong balance sheet, the Company is focused on building commercial partnerships that will enable it to scale into new opportunities. More details will be provided at the investor briefing planned for early June.

– END –

Announcement authorised by the Board of Directors of Genetic Signatures Limited

For further information, please see our website (www.geneticsignatures.com) or contact us:

Caroline Waldron
Chair

caroline.waldron@geneticsignatures.com

T: +61 (0) 2 9870 7580

Daniel Ireland
Investor Relations

daniel.ireland@datair.com.au

0428 607 884

About Genetic Signatures Limited: Genetic Signatures is a molecular diagnostics company specialising in detecting infectious agents utilising its proprietary **3base®** technology that simplifies the genetic complexity of pathogen identification. The Company's automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms in a single test. Genetic Signatures' unique solutions enable laboratories to enhance diagnostic workflow while reducing costs. These rapid results support infection control, appropriate patient management and disease surveillance, while improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.